Hypofractionated post-prostatectomy radiotherapy for prostate cancer to reduce toxicity and improve patient convenience: A Phase I/II trial
IRB/UVa Tracking #: 16604
Principal Investigator: Timothy Showalter
Contact: Amy Smith
Tel: +1 434-243-1619
Official Trial Title: Hypofractionated post-prostatectomy radiotherapy for prostate cancer to reduce toxicity and improve patient convenience: A Phase I/II trial
Primary Purpose: Treatment
UVA Health System, Department of Radiation Oncology seeks men, ages 18 and older with prostate cancer for a research study.
Currently, at UVA, the standard radiation therapy course length for this type of cancer is around 7 ½ -8 weeks. The purpose of this study is to test the safety of a shorter course of radiation therapy at progressively lower dose levels and shorter lengths of treatment (hypofractionated) with patients who have had their prostate removed. We would like to find out what effects (good and bad) the shorter course has on prostate cancer patients and their cancer.
The study will test whether the hypofractionated course works better than the standard therapy course. Participation in this study will require up to 5 study visits per week for up to 5 weeks. Follow-up visits will be conducted at 1 month, 3, 6, 12, and 24 months after completion of radiation therapy.
Department of Radiation Oncology,
Principal Investigator: Timothy Showalter, MD